Precipio (PRPO) Stock Price, News & Analysis

Company Overview

Precipio, Inc. is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput. This platform is complemented by a suite of proprietary reagents and staining kits specifically engineered for hematopathology applications. In addition, Precipio provides specialized molecular assays—including cytogenetics, flow cytometry panels and next-generation sequencing tests—that enable comprehensive profiling of genetic and phenotypic markers in patient samples.

Precipio operates through two primary divisions: a laboratory services arm that performs diagnostic testing on patient specimens using its proprietary technologies, and a product division that markets instruments, reagents and software to hospitals, commercial laboratories and academic research centers. Headquartered in Pittsburgh, Pennsylvania, the company has established strategic partnerships and distribution channels within the United States and is exploring opportunities to expand its presence in select international markets.

Under the leadership of President and CEO Michael Q. McNamara, Precipio has pursued both in-house development and collaborative agreements with academic institutions and industry players to accelerate its product pipeline. Since its founding, the company has remained committed to leveraging innovations in digital pathology and molecular diagnostics, positioning itself as a contributor to the evolving precision medicine paradigm in hematologic oncology.

Key Stats

• Today's Range: $27.75 to $29.70
• 50-Day Range: $24.17 to $32.37
• 52-Week Range: $7.05 to $33.63
• Volume: 26,075 shs
• Average Volume: 23,720 shs
• Market Capitalization: $50.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Precipio Stock Analysis - MarketRank™

Precipio scored higher than 24% of companies evaluated by MarketBeat, and ranked 776th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Precipio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Precipio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Precipio is -113.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precipio is -113.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Precipio has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.48% of the float of Precipio has been sold short.

Short Interest Ratio / Days to Cover

Precipio has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Precipio has recently decreased by 22.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precipio does not currently pay a dividend.

Dividend Growth

Precipio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.61

News Sentiment

Precipio has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Precipio this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for PRPO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $531.00 in company stock, which represents 0.0011% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Precipio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $531.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.60% of the stock of Precipio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

10.45% of the stock of Precipio is held by institutions.

Company Calendar

• Last Earnings: 3/30/2026
• Today: 5/14/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:PRPO
• CIK: 1043961
• Web: www.precipiodx.com
• Phone: (203) 787-7888
• Fax: 402-452-5401
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$360 thousand
• Net Margins: -1.51%
• Pretax Margin: -1.51%
• Return on Equity: -2.78%
• Return on Assets: -1.84%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 1.61
• Quick Ratio: 1.36

Sales & Book Value

• Annual Sales: $24.05 million
• Price / Sales: 2.09
• Cash Flow: $0.78 per share
• Price / Cash Flow: 36.10
• Book Value: $8.31 per share
• Price / Book: 3.39

Miscellaneous

• Outstanding Shares: 1,780,000
• Free Float: 1,489,000
• Market Cap: $50.20 million
• Optionable: No Data
• Beta: 1.38